2019: A year of expansion in psychedelic research, industry, and deregulation

Public and scientific interest into psychedelic drugs has grown steadily over much of the last two decades, before an exponential increase in recent years. We contend that 2019, in particular, involved myriad notable changes in the science, industry, and deregulation of psychedelic drugs. However, it is becoming increasingly difficult for professionals to keep up-to-date on  …


Improved colour blindness symptoms associated with recreational psychedelic use

It is well documented that psychedelic drugs can have a profound effect on colour perception. After previous research involving psychedelic drug ingestion, several participants had written to the authors describing how symptoms of their colour blindness had improved. The Global Drugs Survey runs the world’s largest annual online drug survey. In the Global Drugs Survey  …


Medical cannabis in the UK: From principle to practice

Read the full paper here (open access) Drug Science submits it’s finding concerning the UK Medical cannabis industry. In our recent peer-reviewed publication, Drug Science examines the current barriers to prescribing medical cannabis; ethical issues that arise from that process and we present our recommendations for best practice within this space. In the UK, medical  …


Twenty21 is now live

About Project Twenty21 Project Twenty21 is a registry aiming to monitor the health outcomes of 20,000 patients using cannabis based medicinal products (CBMPs), creating the largest body of evidence in Europe for the safety and efficacy of CBMPs. Drug Science hope that the findings of Project Twenty21 will provide evidence for NHS funding where the  …